Open AccessHepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis
Author(s) -
Shao-Yu Tseng,
Yi-Hsiang Huang,
Tsung-Hsien Chang,
Cherng-Kang Perng,
Yi-Hsiang Huang
Publication year - 2021
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000605
Subject(s) - rifapentine , regimen , medicine , isoniazid , meta analysis , odds ratio , tuberculosis , subgroup analysis , confidence interval , surgery , latent tuberculosis , mycobacterium tuberculosis , pathology
The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP). We performed this updated meta-analysis to compare hepatotoxicity, efficacy and completion rate between these two regimens.